Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.

Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; Italian Liver Cancer group.

Lancet Oncol. 2011 Jul;12(7):654-62. doi: 10.1016/S1470-2045(11)70144-9. Epub 2011 Jun 16.

PMID:
21684210
2.

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study.

Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U; Italian Liver Cancer (ITA.LI.CA) group.

J Hepatol. 2015 Mar;62(3):617-24. doi: 10.1016/j.jhep.2014.10.037. Epub 2014 Oct 30.

PMID:
25450706
3.

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V.

World J Hepatol. 2012 Sep 27;4(9):256-61. doi: 10.4254/wjh.v4.i9.256.

4.

The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.

Gómez-Rodríguez R, Romero-Gutiérrez M, Artaza-Varasa T, González-Frutos C, Ciampi-Dopazo JJ, de-la-Cruz-Pérez G, Sánchez-Ruano JJ.

Rev Esp Enferm Dig. 2012 Jun;104(6):298-304. English, Spanish.

5.

Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria.

De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L, Colledan M, Fagiuoli S, Strazzabosco M.

Liver Transpl. 2010 Apr;16(4):503-12. doi: 10.1002/lt.22039.

6.

Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.

Radu P, Groza I, Iancu C, Al Hajjar N, Andreica V, Sparchez Z.

J Gastrointestin Liver Dis. 2013 Sep;22(3):291-7.

7.

Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.

Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I.

World J Gastroenterol. 2015 May 14;21(18):5654-62. doi: 10.3748/wjg.v21.i18.5654.

8.

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT.

Gastroenterology. 2014 Jun;146(7):1691-700.e3. doi: 10.1053/j.gastro.2014.02.032. Epub 2014 Feb 25.

PMID:
24583061
9.

Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.

Ciria R, López-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllón MD, Luque A, Zurera L, Espejo JJ, Rodríguez-Perálvarez M, Montero JL, de la Mata M, Briceño J.

Eur J Surg Oncol. 2015 Sep;41(9):1153-61. doi: 10.1016/j.ejso.2015.05.023. Epub 2015 Jun 12.

PMID:
26118317
10.

Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment.

Vauthey JN, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, Lerut J, Chapman WC, Hemming AW, Neuhaus P.

J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8.

PMID:
17481532
11.

Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages.

D'Avola D, Iñarrairaegui M, Pardo F, Rotellar F, Marti P, Bilbao JI, Martinez-Cuesta A, Benito A, Alegre F, Mauleón E, Herrero JI, Quiroga J, Prieto J, Sangro B.

Ann Surg Oncol. 2011 Jul;18(7):1964-71. doi: 10.1245/s10434-011-1551-4. Epub 2011 Jan 26.

PMID:
21267791
12.

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group.

Lancet Oncol. 2009 Jan;10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5. Epub 2008 Dec 4.

PMID:
19058754
13.

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY).

Hepatology. 2011 Sep 2;54(3):868-78. doi: 10.1002/hep.24451. Epub 2011 Jun 30.

PMID:
21618574
14.

Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.

Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ.

Ann Surg. 2014 Aug;260(2):329-40. doi: 10.1097/SLA.0000000000000236.

PMID:
24096763
15.

Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center.

Kim SE, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ.

Korean J Hepatol. 2011 Jun;17(2):113-9. doi: 10.3350/kjhep.2011.17.2.113.

16.

Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.

Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE Jr, Gaba RC.

AJR Am J Roentgenol. 2016 Mar;206(3):645-54. doi: 10.2214/AJR.15.14758.

PMID:
26901023
17.

External validation of a simplified BCLC staging system for early hepatocellular carcinoma.

Santambrogio R, Salceda J, Costa M, Kluger MD, Barabino M, Laurent A, Opocher E, Azoulay D, Cherqui D.

Eur J Surg Oncol. 2013 Aug;39(8):850-7. doi: 10.1016/j.ejso.2013.05.001. Epub 2013 May 29.

PMID:
23726257
18.

Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit.

Vitale A, Cucchetti A, Qiao GL, Cescon M, Li J, Ramirez Morales R, Frigo AC, Xia Y, Tuci F, Shen F, Cillo U, Pinna AD.

J Hepatol. 2014 Jun;60(6):1165-71. doi: 10.1016/j.jhep.2014.01.022. Epub 2014 Feb 6.

PMID:
24508550
19.

The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients.

Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN.

Eur J Cancer. 2008 May;44(7):1000-6. doi: 10.1016/j.ejca.2008.02.018. Epub 2008 Mar 11.

PMID:
18337087
20.

BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.

Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnu' L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2015 Jan;35(1):223-31. doi: 10.1111/liv.12649. Epub 2014 Aug 27.

PMID:
25074434

Supplemental Content

Support Center